NovoCure Ltd stock (JE00B6T5S470): Q1 2026 growth meets one?time hit
NovoCure Ltd reported higher Q1 2026 revenue of approximately 174 million USD, representing a 12% year-over-year increase, driven by strong performance in its tumor treating fields therapies for cancer patients. However, the company also incurred a notable one-time charge that negatively impacted its earnings for the quarter. While the underlying business momentum remains positive, the market assesses the sustainability of NovoCure's margin profile by distinguishing between recurring costs and one-off items, particularly as it expands into larger oncology indications.
NovoCure Limited - Ordinary Shares (NQ: NVCR)
This page provides recent news headlines and financial data for NovoCure Limited (NVCR). It includes financial news such as earnings transcripts and revenue reports, analyst ratings, and developments related to FDA approvals for cancer treatments. The articles cover events from late 2024 through early 2026, highlighting significant stock movements and strategic developments for the company.
NovoCure Ltd stock (JE00B6T5S470): mixed Q4 2025 results and new Oppenheimer upgrade draw investor f
NovoCure Ltd, a cancer therapy specialist, is gaining investor attention following its mixed Q4 2025 results and an Oppenheimer analyst upgrade to Outperform. While the company reported strong revenue growth, it also experienced a wider net loss, leading to investor debate about its long-term potential versus execution risks. The article highlights NovoCure's core business model, key revenue drivers, and its significance for US investors in the evolving oncology market.
NovoCure (NVCR) Is Up 9.7% After Raising 2026 Revenue Outlook And Posting Stronger Q1 Sales
NovoCure (NVCR) shares rose 9.7% after the company increased its full-year 2026 net revenue guidance to $690 million–$710 million, up from $675 million–$705 million, following stronger-than-expected first-quarter 2026 sales of $174.06 million. While the higher revenue outlook provides a positive signal for growth, the reported net loss of $71.14 million highlights ongoing concerns regarding cash burn and the timeline to profitability. The article suggests that despite the improved revenue forecast, investors should consider the continuous operating losses against potential future growth catalysts.
NovoCure Ltd stock (JE00B6T5S470): Up 40% YTD on oncology innovation
NovoCure Ltd (NVCR) shares have increased by 40% year-to-date, reaching $18.10, driven by the progress of its Tumor Treating Fields (TTFields) therapy in solid tumor treatment. The company, which specializes in non-invasive anti-mitotic therapy, has a market capitalization of $2.11 billion. Analysts have set a target price of $27.29 for the stock, emphasizing its focus on oncology innovation and its relevance to US healthcare spending trends.
NovoCure (NVCR) Is Up 9.7% After Raising 2026 Revenue Outlook And Posting Stronger Q1 Sales
NovoCure (NVCR) saw its stock rise 9.7% after reporting stronger first-quarter 2026 sales of US$174.06 million and updating its full-year 2026 net revenue outlook to US$690 million–US$710 million. This revised guidance offers new insights into management's view of demand for its tumor treating fields devices. While higher revenue forecasts improve the company's growth narrative, the larger net loss for Q1 2026 highlights ongoing concerns about cash burn and the timeline to sustainable profitability.
A Look At NovoCure (NVCR) Valuation After Raised 2026 Revenue Guidance And Q1 Beat
NovoCure (NVCR) recently announced Q1 2026 revenue that surpassed expectations and increased its full-year 2026 revenue guidance to between US$690 million and US$710 million. This positive news has significantly boosted its share price, with a 62.61% gain over the last month. The company's valuation narrative suggests it is 35.4% undervalued, with a fair value of $26.07 per share, driven by potential regulatory approvals and market expansion for its TTFields therapy.
A Look At NovoCure (NVCR) Valuation After Raised 2026 Revenue Guidance And Q1 Beat
NovoCure (NVCR) has seen a surge in investor attention and share price after reporting strong Q1 2026 revenue and raising its full-year guidance to US$690-710 million. Despite recent gains, a popular narrative suggests the stock is 35.4% undervalued, setting a fair value of $26.07 per share due to potential regulatory approvals and market expansion for its TTFields therapy. The article encourages investors to weigh both the renewed optimism and potential risks before making investment decisions.
[SCHEDULE 13G/A] NovoCure Ltd Amended Passive Investment Disclosure
Soleus Capital Master Fund, L.P. and its affiliated entities have filed an amended Schedule 13G/A, disclosing a 9.1% passive stake in NovoCure Limited (NASDAQ: NVCR). The filing shows beneficial ownership of 10,492,391 ordinary shares, with shared voting and dispositive power among the reporting persons. This percentage is based on 115,820,940 ordinary shares of NovoCure outstanding as of April 24, 2026.
Oncology Company Given Neutral Rating as Q1/26 Beat Sets Up Catalyst
Wedbush Securities reiterated a Neutral rating and an $18 price target for Novocure Ltd. (NVCR) after the oncology company reported a Q1/26 revenue beat of $174.1 million and raised its FY26 revenue guidance to $690–710 million. The company showed strong international Optune adoption and encouraging early launch metrics for Optune Pax in pancreatic cancer, but analysts are awaiting further momentum and clarity on reimbursement. Upcoming catalysts include TRIDENT trial data in Q2/26 and a PMA decision for brain metastases in Q4/26.
Oncology Co. Tests Advanced Cancer Treatments, Reports Q1 2026 Financial Results
Novocure Ltd. (NVCR:NASDAQ) reported a strong Q1 2026 with a 12% revenue increase, significant international patient growth, and positive FDA actions. The company achieved a 74% disease control rate in its PANOVA-4 pancreatic cancer trial and updated its 2026 financial guidance. Several analysts issued 'Buy' or 'Neutral' ratings, highlighting the company's financial health and pipeline progress.
Why NovoCure (NVCR) Is Up 33.2% After FDA Clears Optune Pax And Guidance Ticks Higher
NovoCure (NVCR) stock rose 33.2% after the U.S. FDA cleared Optune Pax for pancreatic cancer, leading to a modest increase in their full-year 2026 revenue guidance to US$690 million–US$710 million. Despite widening net losses, the company is expanding its tumor treating fields footprint, with the Optune Pax launch reinforcing its focus on new indications. Investors are now watching whether pancreatic and lung cancer can offset operating costs and validate the company's growth story, with the TRIDENT Phase 3 GBM data remaining a key catalyst.
Why NovoCure (NVCR) Is Up 33.2% After FDA Clears Optune Pax And Guidance Ticks Higher
NovoCure (NVCR) shares rose 33.2% after the U.S. FDA cleared Optune Pax for locally advanced pancreatic cancer and the company modestly raised its full-year 2026 revenue guidance to US$690 million–US$710 million. Despite widening net losses, the successful launch and physician adoption of Optune Pax, along with ongoing clinical trials, reinforce the company's commitment to expanding its tumor treating fields technology. Analysts are closely watching whether new indications can offset rising operating costs and validate the long-term growth story, with some forecasting significant revenue and earnings growth by 2029.
Wells Fargo Maintains Novocure(NVCR.US) With Hold Rating, Raises Target Price to $17
Wells Fargo has reiterated its "Hold" rating for Novocure (NVCR.US) and increased its target price for the stock to $17. This indicates a continued cautious but not entirely negative outlook from the investment bank regarding Novocure's future performance.
NovoCure’s Optune Pax Win And TRIDENT Data Shape Growth Outlook
NovoCure (NVCR) recently secured FDA approval and launched Optune Pax for pancreatic cancer, broadening its market beyond glioblastoma. This new revenue stream, alongside upcoming Phase 3 TRIDENT data for glioblastoma, is critical for the company to scale its operations and move towards profitability, supporting its 2026 revenue guidance of US$690 million to US$710 million. Investors are watching early adoption metrics and trial results to assess the long-term growth potential and financial stability of NovoCure's tumor treating fields platform.
NovoCure Ltd (NVCR) Shares Surge 9.3% -- What GF Score of 70 Tel
NovoCure Ltd (NVCR) shares surged 9.3% to $16.62, currently trading below its estimated fair value of $19.67, making it "Modestly Undervalued" despite a high P/E ratio. The company has a GF Score of 70/100, indicating potential for long-term returns, though it faces challenges with profitability (2/10) and significant insider selling totaling $2.3 million over the past three months.
Here's What Analysts Are Forecasting For NovoCure Limited (NASDAQ:NVCR) After Its First-Quarter Results
NovoCure Limited recently released its first-quarter results, and analysts have updated their forecasts for the company. The consensus among analysts is an upgrade in their earnings and revenue predictions, reflecting a more optimistic outlook on NovoCure's future performance. Investors will be watching how these revised expectations translate into stock performance.
NovoCure’s Optune Pax Win And TRIDENT Data Shape Growth Outlook
NovoCure has received FDA approval and launched Optune Pax for locally advanced pancreatic cancer in the U.S., expanding its therapeutic reach beyond glioblastoma. This new revenue stream, along with upcoming Phase 3 TRIDENT data for newly diagnosed glioblastoma, are critical for accelerating growth, managing ongoing net losses, and broadening its tumor treating fields platform across multiple cancer indications. Investors are closely watching the adoption rates of Optune Pax and the TRIDENT trial results to assess the company's financial trajectory and path to profitability.
NovoCure Reports Q1 2026 Results: Full Earnings Call Transcript
NovoCure reported a strong Q1 2026 with double-digit growth in active patients and net revenues, driven by the successful U.S. launch of Optune Pax for pancreatic cancer. The company raised its full-year revenue guidance to $690 million to $710 million and is making progress towards profitability. Key highlights include promising early adoption of Optune Pax and advancements in GBM and lung cancer programs, with upcoming data from the Phase 3 Trident trial.
NovoCure Ltd (NVCR) Shares Surge 9.3% -- What GF Score of 70 Tells Investors
NovoCure Ltd (NVCR) shares surged 9.3% to $16.62, currently trading 15.5% below its estimated fair value of $19.67 according to GuruFocus' GF Value™. The company has a GF Score™ of 70/100, indicating potential for long-term returns, with strong valuation but weak profitability and recent insider selling of $2.3 million. Investors are advised to consider the undervaluation alongside concerns raised by insider activity and low profitability scores.
NovoCure (NVCR) Earnings Story Centers On 20.6% Revenue Growth Versus Ongoing Losses
NovoCure (NVCR) started 2026 with Q1 results showing 20.6% annual revenue growth, reaching US$655.4 million on a trailing 12-month basis, despite still recording a net loss of US$136.2 million. The company's unique position involves strong revenue growth and forecast earnings growth of 73.9% annually, which bulls believe will eventually absorb current losses, contrasting with bears who point to a five-year trend of widening losses and ongoing unprofitability. The article explores both the bullish arguments, focusing on revenue and future earnings potential, and the bearish concerns about persistent losses and cost headwinds.
Novocure reports Q1 2026 revenue $174.1M, adjusted EBITDA $(0.3)M, net loss $71.1M
Novocure announced its first-quarter 2026 financial results, reporting total net revenues of $174.1 million, a 12% increase year-over-year, and a net loss of $71.1 million. The company's adjusted EBITDA was $(0.3) million, with gross margin improving to 78%. Key business highlights include the continued commercial rollout of Optune products, particularly the initial uptake of Optune Pax following U.S. FDA approval for pancreatic cancer.
H.C. Wainwright Maintains Novocure(NVCR.US) With Buy Rating, Cuts Target Price to $48
H.C. Wainwright has reiterated its Buy rating for Novocure (NVCR.US) but has adjusted its target price downwards to $48. This decision reflects the firm's continued positive outlook on the company despite a reduction in the price target.
NovoCure (NVCR) Earnings Story Centers On 20.6% Revenue Growth Versus Ongoing Losses
NovoCure (NVCR) reported Q1 2026 results showing 20.6% annual revenue growth while still incurring significant net losses. Despite the revenue growth and a forecast of 73.9% annual earnings growth, the company has seen widening losses over the past five years, raising concerns about its path to profitability. The stock trades at a P/S discount compared to peers, and while a DCF analysis suggests significant upside, ongoing losses and share price volatility prompt investor caution.
NovoCure (NVCR) Q1: EPS -0.62 (miss vs -0.51 est.), Revenue $174.1M (beat vs $167.87M) -- 39.3% Undervalued by GF Value?
NovoCure Ltd (NVCR) reported its first-quarter 2026 results, with net revenues rising 12% to $174.1 million, surpassing analyst estimates. However, the company missed EPS estimates with a GAAP loss per share of $0.62, primarily due to higher operating expenses including a significant non-cash share-based compensation charge. Despite the EPS miss, active patient growth, gross margin expansion, and a solid liquidity position indicate commercial momentum and potential for future growth.
NovoCure Ltd reports first quarter 2026 earnings performance
NovoCure Ltd has released its financial outcomes for the first quarter ending March 31, 2026, via a press release. While the company provided key updates on its business and financial standing, specific revenue, profit metrics, or forward guidance were not disclosed in this initial communication. The release was previously scheduled for April 30, and further details on the reported metrics are anticipated.
New pancreatic cancer launch helps Novocure reach $174M in Q1 revenue
Novocure announced strong first-quarter 2026 financial results, with total net revenues reaching $174.1 million, a 12% increase year-over-year, driven primarily by active patient growth in European markets. A significant contributor to this growth was the U.S. FDA approval and launch of Optune Pax for locally advanced pancreatic cancer, alongside positive developments for other therapies and an uplifted full-year financial guidance for 2026. The company remains focused on expanding the use of its Tumor Treating Fields therapy and achieving sustainable growth and profitability.
NovoCure: Q1 Earnings Snapshot
NovoCure Ltd. (NVCR) reported a Q1 loss of $71.1 million, or 62 cents per share, missing Wall Street's expectation of a 40 cents per share loss. Despite this, the oncology drug developer's revenue of $174.1 million exceeded analysts' forecasts of $167.9 million. The company projects full-year revenue to be between $690 million and $710 million.
NovoCure (NASDAQ: NVCR) grows Q1 2026 revenue while investing in new cancer indications
NovoCure (NASDAQ: NVCR) reported a 12% increase in Q1 2026 revenue to $174.1 million, driven by international growth and increased adoption of its Optune products. Despite this revenue growth and an improved gross margin of 78%, the company's net loss widened to $71.1 million, largely due to higher operating expenses including a significant non-cash share-based compensation expense related to the FDA approval of Optune Pax. NovoCure continues to invest in new cancer indications and research, maintaining a strong cash position to fund its operations.
Novocure (NASDAQ: NVCR) grows Q1 revenue and raises 2026 outlook
Novocure reported a 12% year-over-year revenue increase to $174.1 million in Q1 2026, primarily driven by growth in European Optune Gio patients and contributions from Optune Lua and the Zai Lab partnership. The company also raised its full-year 2026 revenue guidance to $690–$710 million and narrowed its Adjusted EBITDA guidance to $(15) million to breakeven. Key achievements include U.S. FDA approval for Optune Pax for pancreatic cancer, new coverage decisions in various regions, and positive Phase 2 clinical data for metastatic pancreatic cancer.
NovoCure Limited 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:NVCR) 2026-04-30
NovoCure Limited (NASDAQ:NVCR) released its Q1 2026 earnings, reporting an EPS of -$0.62 which missed estimates by $0.11, and revenue of $174.06M, beating estimates by $6.28M with a 12.30% year-over-year increase. The company published a slide deck in conjunction with its earnings call.
NovoCure Ltd 1Q 2026: Revenue $174.06M, EPS ($0.62) — 10-Q Summary
NovoCure Ltd (NVCR) reported its first-quarter 2026 results, showing a 12.3% year-over-year revenue increase to $174.06 million. Despite this growth, the company posted a net loss of ($71.14 million) and diluted EPS of ($0.62), a worsening from the prior year's loss. The revenue growth was driven by international patient growth and U.S. market gains, alongside product expansions and improved gross margin.
Novocure Ltd expected to post a loss of 51 cents a share - Earnings Preview
Novocure Ltd (NVCR) is projected to report an earnings loss of 51 cents per share. This preview, provided by Refinitiv and published by Reuters, is a short news item indicating the company's financial outlook ahead of its earnings release.
Novocure earnings in focus as new pancreatic therapy debuts
Novocure's first-quarter earnings report on Thursday will be scrutinized by investors to see if recent regulatory approvals, particularly for its new pancreatic therapy, can counteract declining revenue and widening losses. Analysts anticipate a loss of $0.49 per share on $167.77 million in revenue, leading to questions about the commercial launch success of Optune Pax, the company's path to profitability, and its international expansion. Despite challenges, analysts rate the stock a "Buy" with a significant upside potential.
NovoCure (NASDAQ: NVCR) director converts options into 21,500 shares
NovoCure Ltd director Vernon W. Anthony exercised stock options to acquire 21,500 Ordinary Shares at $11.39 per share. These were option exercises and not open-market purchases. Following the transaction, Mr. Anthony directly holds 200,602 Ordinary Shares, and the exercised option grant for 21,500 shares has been fully utilized.
Vanguard (NVCR) holds 6.34M shares, 5.57% stake disclosed in 13G
Vanguard Portfolio Management has disclosed a 5.57% stake in Novocure Ltd (NVCR), holding 6,339,994 shares as of March 31, 2026. This ownership, reported in a Schedule 13G filing, indicates Vanguard possesses sole voting power over 88,293 shares and sole dispositive power over all 6,339,994 shares. The filing was signed on April 28, 2026, by Ashley Grim.
NovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of "Hold" by Analysts
Seven analysts have issued a "Hold" rating for NovoCure Limited (NASDAQ:NVCR), with a 12-month consensus price target of $26.93. Despite beating EPS expectations last quarter, the company remains unprofitable, trading around $12.47 per share. Insiders have recently sold over 140,000 shares, while institutional investors have increased their holdings.
Earnings Preview: Novocure to Report Financial Results Pre-market on April 30
Novocure (NASDAQ: NVCR) is scheduled to release its financial results for the quarter ending March 31, 2026, before the market opens on Tuesday, April 30. Analysts are forecasting the company to report earnings of ($0.08) per share and revenue of $161.42 million. Investors will be closely watching these figures for insights into the company's performance.
CEO Frank Leonard's new NovoCure (NASDAQ: NVCR) contract outlines pay
NovoCure (NASDAQ: NVCR) has detailed the compensation package for its new CEO, Frank Leonard, whose employment agreement became effective January 1, 2026. The contract includes an annual base salary of CHF 750,000, a target annual cash bonus of 90% of his base salary, and eligibility for equity awards. The agreement also outlines significant relocation and tax indemnification benefits, as well as severance terms for various termination scenarios and change-in-control protections.
NovoCure (NVCR) to Release Quarterly Earnings on Thursday
NovoCure (NASDAQ:NVCR) is scheduled to release its Q1 2026 earnings before the market opens on Thursday, April 30th. Analysts are anticipating an EPS of ($0.4871) and revenue of $167.77 million. The company, which reported a ($0.22) EPS in the last quarter, currently holds a consensus "Hold" rating with an average price target of $26.93.
Total debt per share of NovoCure Ltd. – SWB:038
This article focuses on the "Total debt per share" metric for NovoCure Ltd., traded on the Stuttgart Stock Exchange under the symbol 038. It provides a brief financial overview within the context of health technology and medical specialties, indicating that the market is currently closed with no trades.
NovoCure Ltd stock (JE00B6T5S470): Is tumor treating fields therapy strong enough to unlock new upsi
NovoCure Ltd. is a medtech company specializing in Tumor Treating Fields (TTFields) therapy for hard-to-treat cancers like glioblastoma and mesothelioma. The company's business model relies on recurring revenue from device rentals, with Optune as its flagship product. Future growth hinges on expanding indications through clinical trials for lung, ovarian, and pancreatic cancers, alongside navigating reimbursement challenges and competitive pressures in the oncology market.
[DEF 14A] NovoCure Ltd Definitive Proxy Statement
NovoCure Ltd. (NVCR) has filed a definitive proxy statement (DEF 14A) for its annual general meeting on June 3, 2026. Shareholders will vote on electing directors, ratifying EY Global as auditor, approving executive compensation, and amending the 2024 Omnibus Incentive Plan. The proposed amendment to the incentive plan includes increasing the share reserve by 9,000,000 shares, extending its term to 2036, removing liberal share recycling, and introducing a one-year minimum vesting requirement.
NovoCure Ltd stock (JE00B6T5S470): Is tumor treating fields therapy strong enough to unlock new upsi
This report details NovoCure's business model, its Tumor Treating Fields (TTFields) technology, market relevance, risks, and watchpoints for investors, particularly in the United States and English-speaking markets. The company develops non-invasive therapy for hard-to-treat cancers like glioblastoma and mesothelioma, relying on recurrent revenue from equipment sales and array changes. Its growth hinges on expanding indications through clinical trials, securing reimbursement, and driving adoption by oncologists.
NovoCure Ltd stock (JE00B6T5S470): Does tumor treating fields therapy hold the key to oncology break
NovoCure Ltd is recognized for its innovative Tumor Treating Fields (TTFields) technology, which uses low-intensity electric fields to disrupt cancer cell division. The company's core product, Optune, is approved for glioblastoma and is expanding into other cancers like non-small cell lung cancer, mesothelioma, and pancreatic cancer. NovoCure's business model relies on device sales and service, offering a capital-light approach to investors compared to traditional pharmaceuticals.
NovoCure Ltd (NVCR) Stock Up 3.8% and Still Undervalued -- GF Sc
NovoCure Ltd (NVCR) shares recently rose 3.8% to $12.62, significantly below its GF Value™ estimate of $19.63, suggesting it is undervalued by 35.7%. Despite this, the stock carries risks as indicated by a high P/E ratio of 1862.8x and negative insider activity, with $2.3 million in insider sales over the last three months and no buying. The GF Score™ of 65/100 points to above-average potential primarily driven by growth, but profitability issues remain a concern.
NVCR Reiterated by Wedbush -- Price Target Maintained at $18.00
Wedbush has maintained a "Neutral" rating and an $18.00 price target for NovoCure (NVCR), citing a cautious outlook despite the stock appearing 37.9% undervalued by GuruFocus's GF Value™. The company's GF Score™ of 65/100 reflects moderate performance with strong growth but weak profitability. Investors are advised caution due to a "Possible Value Trap" indication and recent insider selling of $2.3 million worth of shares.
Tangible book value per share of NovoCure Ltd. – GETTEX:038
This article provides the tangible book value per share for NovoCure Ltd. (GETTEX:038). It presents financial data related to the company's performance, including period values, changes, and percentage changes, with data sourced from ICE Data Services, FactSet, and Quartr for SEC filings.
NovoCure's (NVCR) Neutral Rating Reaffirmed at Wedbush
Wedbush has reiterated a "Neutral" rating for NovoCure (NVCR), setting an $18.00 price target, which suggests a 47.5% upside. Despite beating EPS estimates with ($0.22) and achieving an 8.2% YoY revenue increase to $174.35M, the company remains unprofitable. Insider sales have occurred, though institutional investors hold a significant stake.
Is NovoCure’s (NVCR) Leadership Consolidation Clarifying Its Innovation Strategy Or Complicating Governance Signals?
NovoCure recently appointed Uri Weinberg as Chief Medical Officer in addition to Chief Innovation Officer, with a modest stipend increase, aiming to align medical and innovation oversight for its Tumor Treating Fields programs. This leadership consolidation comes amidst ongoing insider share sales and clinical trial progress for pancreatic cancer and brain metastases, raising questions for investors about the company's long-term execution, governance, and profitability goals, which project significant revenue growth by 2029. The article discusses how this move impacts NovoCure's investment narrative and risk profile, especially concerning its reliance on TTFields and reimbursement challenges.
